Frazier Lifesciences Acquisition Corporation is a newly incorporated blank check company, incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, which we refer to as our initial business combination. While Frazier Lifesciences Acquisition Corporation may pursue an initial business combination opportunity in any business, industry, sector or geographical location, it intends to capitalize on the ability of its management team to identify promising opportunities in the biotechnology sector.
Company profile
Ticker
NAMS, NAMS
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Latest filings (excl ownership)
15-12G
Securities registration termination
2 Dec 22
8-K
Entry into a Material Definitive Agreement
23 Nov 22
25-NSE
Exchange delisting
22 Nov 22
25-NSE
Exchange delisting
22 Nov 22
25-NSE
Exchange delisting
22 Nov 22
425
Business combination disclosure
16 Nov 22
8-K
Submission of Matters to a Vote of Security Holders
15 Nov 22
10-Q
2022 Q3
Quarterly report
9 Nov 22
DEFM14A
Proxy related to merger
18 Oct 22
425
Business combination disclosure
17 Oct 22
Latest ownership filings
SC 13G/A
Alyeska Investment Group, L.P.
15 Feb 23
SC 13G/A
Flynn James E
1 Dec 22
SC 13D/A
VIKING GLOBAL INVESTORS LP
25 Nov 22
4
OLE ANDREAS HALVORSEN
25 Nov 22
4
David Joseph Topper
23 Nov 22
4
MICHAEL BIGHAM
23 Nov 22
4
Krishna R Polu
23 Nov 22
4
Robert Jr. Baltera
23 Nov 22
4
Carol Giltner Gallagher
23 Nov 22
SC 13D/A
Frazier Lifesciences Sponsor LLC
23 Nov 22
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 375.55 k | 375.55 k | 375.55 k | 375.55 k | 375.55 k | 375.55 k |
Cash burn (monthly) | 79.97 k | 21.67 k | 764.53 k | 423.63 k | 79.97 k | 17.92 k |
Cash used (since last report) | 1.51 mm | 408.60 k | 14.42 mm | 7.99 mm | 1.51 mm | 337.89 k |
Cash remaining | -1.13 mm | -33.06 k | -14.04 mm | -7.61 mm | -1.13 mm | 37.65 k |
Runway (months of cash) | -14.2 | -1.5 | -18.4 | -18.0 | -14.2 | 2.1 |
Institutional ownership, Q2 2023
5.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 5.07 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Morningside Venture Investments | 5.07 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Nov 22 | Gallagher Carol Giltner | Class B Ordinary Shares Class A Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 30,000 | 0.00 | 0 |
22 Nov 22 | Polu Krishna R | Class B Ordinary Shares Class A Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 30,000 | 0.00 | 0 |
22 Nov 22 | Robert Jr. Baltera | Class B Ordinary Shares Class A Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 30,000 | 0.00 | 0 |
22 Nov 22 | Bigham Michael | Class B Ordinary Shares Class A Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 30,000 | 0.00 | 0 |
22 Nov 22 | David Joseph Topper | Class B Ordinary Shares Class A Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 30,000 | 0.00 | 0 |
News
RBC Capital Maintains Outperform on NewAmsterdam Pharma, Raises Price Target to $31
29 Feb 24
NewAmsterdam Pharma Reports Full Year 2023 EPS $(2.15) Vs $(1.19) YoY; Revenue $14.1M Vs $102.7M YoY
28 Feb 24
NewAmsterdam Pharma Prices $175.3M Public Offering Of Ordinary Shares And Pre-Funded Warrants
14 Feb 24
Press releases
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
28 Feb 24
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
13 Feb 24
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
13 Feb 24
NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
1 Feb 24